Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 22;12(8):2010. doi: 10.3390/cancers12082010

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Drug-sensitivity tests with erdafitinib and/or cetuximab against PDSX-tumor growth in mice. (A–C), left. Changes in the relative subcutaneous tumor volumes of HC6T (A), HC20T, (B) and HC1T (C) xenografts during drug treatments. (A–C), right. The fraction of proliferating cells (%) monitored by Ki67 expression for each treatment group. The mean values are shown as bars with raw data points in symbols of various shape. Among HC20T PDSX mice, one of the three tumors in the erdafitinib monotherapy group disappeared (complete response), and it is not included in the figure (B, right). The statistical significance of the data difference is shown; *, p < 0.05; **, p < 0.01; ***, p < 0.001; or ****, p < 0.0001; in one-way or two-way ANOVA followed by Tukey’s post-test.